311 related articles for article (PubMed ID: 29595655)
1. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.
Tan G; Chu C; Gui X; Li J; Chen Q
Medicine (Baltimore); 2018 Mar; 97(13):e0197. PubMed ID: 29595655
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of circulating cell-free DNA in the survival of breast cancer patients: A systemic review and meta-analysis.
Yang J; Cheng L; Zhang J; Chen L; Wang D; Guo X; Ma X
Medicine (Baltimore); 2018 Jul; 97(28):e11417. PubMed ID: 29995790
[TBL] [Abstract][Full Text] [Related]
3. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis.
Basnet S; Zhang ZY; Liao WQ; Li SH; Li PS; Ge HY
J Cancer; 2016; 7(9):1105-13. PubMed ID: 27326254
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
Li B; Pu K; Ge L; Wu X
Gene; 2019 Sep; 714():143993. PubMed ID: 31330238
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of the C-reactive protein to albumin ratio in cancer: An updated meta-analysis.
Cui X; Jia Z; Chen D; Xu C; Yang P
Medicine (Baltimore); 2020 Apr; 99(14):e19165. PubMed ID: 32243358
[TBL] [Abstract][Full Text] [Related]
7. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of serum amyloid A in solid tumors: a meta-analysis.
Lin HY; Tan GQ; Liu Y; Lin SQ
Cancer Cell Int; 2019; 19():62. PubMed ID: 30930691
[TBL] [Abstract][Full Text] [Related]
9. High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.
Luo Y; Zhang X; Mo M; Tan Z; Huang L; Zhou H; Wang C; Wei F; Qiu X; He R; Chen G
Medicine (Baltimore); 2016 Apr; 95(15):e3337. PubMed ID: 27082587
[TBL] [Abstract][Full Text] [Related]
10. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
[TBL] [Abstract][Full Text] [Related]
11. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
Yang X; Zhang K; Zhang C; Peng R; Sun C
BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
[TBL] [Abstract][Full Text] [Related]
13. Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
Li C; Yuan Q; Deng T; Xu G; Hou J; Zheng L; Wu G
Breast Cancer; 2023 Nov; 30(6):965-975. PubMed ID: 37470943
[TBL] [Abstract][Full Text] [Related]
14. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
Hussein NA; Mohamed SN; Ahmed MA
Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of circulating tumor cells in patients with bladder cancer: A meta-analysis.
Jiang H; Gu X; Zuo Z; Tian G; Liu J
PLoS One; 2021; 16(7):e0254433. PubMed ID: 34242363
[TBL] [Abstract][Full Text] [Related]
16. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis.
Jiang H; Li H
BMC Cancer; 2021 Feb; 21(1):149. PubMed ID: 33568081
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis.
Lee JH; Jeong H; Choi JW; Oh HE; Kim YS
Medicine (Baltimore); 2018 Oct; 97(42):e12862. PubMed ID: 30334995
[TBL] [Abstract][Full Text] [Related]
18. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis.
Zhang S; Cheng T
Ann Med; 2024 Dec; 56(1):2337729. PubMed ID: 38569199
[TBL] [Abstract][Full Text] [Related]
20. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]